Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | CASP6 | P55212 | 4/20 | 0.54 |
| ▸ | NSD2 | O96028 | 3/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.54 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 2/20 | 0.51 |
| ▸ | DUSP5 | Q16690 | 2/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702480 | 1.00 | NT5E (0.71) | NT5EPTPN1CASP6NSD2DUSP3 | |
| SCHEMBL10623046 | 1.00 | NT5E (0.71) | NT5EPTPN1CASP6NSD2DUSP3 | |
| Silver SCHEMBL11309326 | 0.97 | NT5E (0.71) | NT5EPTPN1CASP6NSD2DUSP3 | |
| SCHEMBL4115385 | 0.87 | CASP6 (0.71) | NT5EPTPN1CASP6NSD2DUSP3 | |
| SCHEMBL11022672 | 0.85 | NT5E (0.78) | NT5ECASP6NSD2DUSP3PTPN5 | |
| SCHEMBL10623050 | 0.83 | NT5E (1.00) | NT5ECASP6NSD2DUSP3PTPN5 | |
| SCHEMBL10332181 | 0.83 | NT5E (1.00) | NT5ECASP6NSD2DUSP3PTPN5 | |
| SCHEMBL156692 | 0.83 | NT5E (1.00) | NT5ECASP6NSD2DUSP3PTPN5 | |
| SCHEMBL1070219 | 0.83 | PTPN1 (0.58) | NT5EPTPN1CASP6NSD2DUSP3 | |
| SCHEMBL8008837 | 0.83 | NT5E (0.56) | NT5EPTPN1CASP6NSD2DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539803-B | Direct red/direct violet dye compound and preparation method and application thereof | 广东省科学院测试分析研究所(中国广州分析测试中心) | 2024-08-30 | — | — | CN | claimed |
| CN-114539803-A | Direct red/direct violet dye compound and preparation method and application thereof | 广东省科学院测试分析研究所(中国广州分析测试中心) | 2022-05-27 | — | — | CN | claimed |
| CN-102408754-B | Brightening disperse red 3B dye composition and preparation method thereof | UNIV SOOCHOW | 2014-01-08 | — | — | CN | claimed |
| CN-102408754-A | Brightening disperse red 3B dye composition and preparation method thereof | UNIV SOOCHOW | 2012-04-11 | — | — | CN | claimed |
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2009-12-10 | — | — | US | claimed |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | ITALFARMACO, S. A. (ES) | 2009-03-19 | — | — | US | claimed |
| EP-1994929-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2008-11-26 | — | — | EP | claimed |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | ITALFARMACO, S.A. (ES) | 2006-07-20 | — | — | US | claimed |
| EP-1602644-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | Italfarmaco, S.A. (ES) | 2005-12-07 | — | — | EP | claimed |
| CN-114539803-B | Direct red/direct violet dye compound and preparation method and application thereof | 广东省科学院测试分析研究所(中国广州分析测试中心) | 2024-08-30 | — | — | CN | disclosed |
| US-11735719-B2 | Reduced graphene oxide/manganese(IV) oxide nanocomposite and electrode comprising same, method of manufacture of various graphene material/metal oxide nanocomposites | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2023-08-22 | — | — | US | disclosed |
| CN-114539803-A | Direct red/direct violet dye compound and preparation method and application thereof | 广东省科学院测试分析研究所(中国广州分析测试中心) | 2022-05-27 | — | — | CN | disclosed |
| US-20210159490-A1 | REDUCED GRAPHENE OXIDE/MANGANESE(IV) OXIDE NANOCOMPOSITE AND ELECTRODE COMPRISING SAME, METHOD OF MANUFACTURE OF VARIOUS GRAPHENE MATERIAL/METAL OXIDE NANOCOMPOSITES | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2021-05-27 | — | — | US | disclosed |
| CN-102408754-B | Brightening disperse red 3B dye composition and preparation method thereof | UNIV SOOCHOW | 2014-01-08 | — | — | CN | disclosed |
| EP-1602644-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | Italfarmaco, S.A. (ES) | 2005-12-07 | — | — | EP | disclosed |
| US-6001934-A | HEAT OXIDATION CROSSLINKING OF POLYARYLENE SULFIDE RESIN | TONEN CHEMICAL CO. (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0900817-A2 | Process for the preparation of a functional group-containing polyarylene sulfide resin | Tonen Chemical Corporation (JP) | 1999-03-10 | — | — | EP | disclosed |
| US-5256199-A | Cement admixture | KAO CORPORATION (JP) | 1993-10-26 | — | — | US | disclosed |
| EP-0469625-A2 | Cement admixture | Kao Corporation (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-4973672-A | Water-soluble aminonaphthol disazo dyestuffs, their preparation and their use | CASSELLA AKTIENGESELLSCHAFT (DE) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | NQO2, SQLE, SQOR | THRB 4784/4885NT5E 1438/4885PTPN1 892/4885 |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | SUCNR1, NR1H4, CYP2B6 | THRB 2224/4885NT5E 3737/4885PTPN1 1567/4885 |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | SUCNR1, NR1H4, CYP2B6 | THRB 2260/4885NT5E 3754/4885PTPN1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.